eCommons@AKU
Medical College Documents

Medical College, Pakistan

2-16-2022

A review of coronaviruses associated with Kawasaki Disease:
Possible implications for pathogenesis of the Multisystem
Inflammatory Syndrome associated with COVID-19
Fatima Farrukh Shahbaz
Aga Khan University, fatima.shahbaz@aku.edu

Russell Seth Martins
Aga Khan University, russell.martins@aku.edu

Abdullah Umair
Aga Khan University, abdullah.umair@aku.edu

Ronika Devi Ukrani
Aga Khan University, ronika.ukrani@aku.edu

Kauser Jabeen
Aga Khan University, kausar.jabeen@aku.edu

See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_mc
Part of the Anatomy Commons, Immunology and Infectious Disease Commons, Laboratory and Basic
Science Research Commons, Pathology Commons, Pediatrics Commons, and the Viruses Commons

Recommended Citation
Shahbaz, F. F., Martins, R. S., Umair, A., Ukrani, R. D., Jabeen, K., Sohail, M., Khan, E. (2022). A review of
coronaviruses associated with Kawasaki Disease: Possible implications for pathogenesis of the
Multisystem Inflammatory Syndrome associated with COVID-19. Clinical medicine insights. Pediatrics.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_mc/261

Authors
Fatima Farrukh Shahbaz, Russell Seth Martins, Abdullah Umair, Ronika Devi Ukrani, Kauser Jabeen, M
Rizwan Sohail, and Erum Khan

This review article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_mc/261

1075319
review-article2022

PDI0010.1177/11795565221075319Clinical Medicine Insights: PediatricsShahbaz et al

A Review of Coronaviruses Associated With Kawasaki
Disease: Possible Implications for Pathogenesis of the
Multisystem Inflammatory Syndrome Associated With
COVID-19

Clinical Medicine Insights: Pediatrics
Volume 16: 1–12
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/11795565221075319
https://doi.org/10.1177/11795565221075319

Fatima Farrukh Shahbaz1 , Russell Seth Martins1, Abdullah Umair1,
Ronika Devi Ukrani1 , Kausar Jabeen2, M Rizwan Sohail3
and Erum Khan4
1Medical

College, Aga Khan University Hospital, Karachi, Pakistan. 2Section of Microbiology,
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi,
Pakistan. 3Mayo Clinic College of Medicine and Science, Rochester, MN, USA. 4Section of
Microbiology, Department of Pathology and Laboratory Medicine, Aga Khan University Hospital,
Karachi, Pakistan.

ABSTRACT: Multisystem Inflammatory Syndrome in Children (MIS-C), representing a new entity in the spectrum of manifestations of COVID-19,
bears symptomatic resemblance with Kawasaki Disease (KD). This review explores the possible associations between KD and the human coronaviruses and discusses the pathophysiological similarities between KD and MIS-C and proposes implications for the pathogenesis of MIS-C in
COVID-19. Since 2005, when a case-control study demonstrated the association of a strain of human coronavirus with KD, several studies have
provided evidence regarding the association of different strains of the human coronaviruses with KD. Thus, the emergence of the KD-like disease
MIS-C in COVID-19 may not be an unprecedented phenomenon. KD and MIS-C share a range of similarities in pathophysiology and possibly
even genetics. Both share features of a cytokine storm, leading to a systemic inflammatory response and oxidative stress that may cause vasculitis and precipitate multi-organ failure. Moreover, antibody-dependent enhancement, a phenomenon demonstrated in previous coronaviruses,
and the possible superantigenic behavior of SARS-CoV-2, possibly may also contribute toward the pathogenesis of MIS-C. Lastly, there is some
evidence of complement-mediated microvascular injury in COVID-19, as well as of endotheliitis. Genetics may also represent a possible link
between MIS-C and KD, with variations in FcγRII and IL-6 genes potentially increasing susceptibility to both conditions. Early detection and
treatment are essential for the management of MIS-C in COVID-19. By highlighting the potential pathophysiological mechanisms that contribute
to MIS-C, our review holds important implications for diagnostics, management, and further research of this rare manifestation of COVID-19.
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Background

results frequently seen in KD patients.5 Moreover, some studies propose the existence of a hitherto unidentified respiratory
virus (the “KD agent”).4,6 The viral theory of KD pathogenesis
is supported by the epidemiological, clinical, histopathological,
and laboratory features of KD.3 One group of respiratory
viruses mentioned in association with Kawasaki-like symptoms are the human coronaviruses (HCoVs).7 Moreover,
though KD and MIS-C are separate entities that differ when it
comes to age and geographic areas, similarities exist in how
they present clinically, as is summarized in Table 1. This review
summarizes the literature exploring the association and commonalities between KD and the human coronaviruses and discusses the implications for the pathogenesis of MIS-C in
COVID-19.

On May 14, 2020, the CDC issued an advisory regarding a
disease with similar symptoms to Kawasaki Disease (KD) in
pediatric patients exposed to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). However, despite being
life-threatening, the disease is considered a rare complication of SARS-CoV-2 infection.1 The WHO classified this
Kawasaki-like disease as “multisystem inflammatory syndrome in children and adolescents temporally related to
COVID-19 (MIS-C)” (also known as Pediatric Multisystem
Inflammatory Syndrome temporally associated with SARSCoV-2; PIMS-TS).2 With the COVID-19 (coronavirus disease 2019) pandemic looming large, the emergence of MIS-C
has brought renewed attention and interest to KD.1
While the specifics are yet unknown, the pathogenesis
of KD is commonly thought to involve a post-infectious
etiology.3 It has been repeatedly hypothesized that there
exists a connection between respiratory viruses and Kawasaki
Disease,4 with positive viral polymerase chain reaction (PCR)

The Human Coronaviruses and KD

In 2005, Esper et al7 reported a possible association of a strain
of HCoV-NL63 (termed New Haven Coronavirus) with KD
in a case-control study of 11 KD patients and 22 controls
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Table 1. Similarities and differences in MIS-C and KD.
MIS-C

KD

Age

0-19 years8 (median age 8-99)

<5 years3 (median age 39)

Geographic Area

Europe, North America, South America9

Asia (Japan, South Korea, Taiwan)3

Clinical similarities8,10

Fever ⩾ 3 days

Fever ⩾ 5 days

Rash

Polymorphous rash

Bilateral non-purulent conjunctivitis

Bilateral non-purulent conjunctivitis

Mucocutaneous inflammation signs (oral, hands,
feet)

Oral mucous membrane changes (cracked and
erythematous lips, strawberry tongue)

Cardiovascular: Features of myocardial dysfunction,
pericarditis, valvulitis, or coronary abnormalities

Changes in extremities (erythema of hands and feet,
desquamation)

Gastrointestinal: Diarrhea, vomiting, abdominal pain

Cardiovascular: Coronary artery abnormalities, decreased
LV function, mitral regurgitation, pericardial effusion
Gastrointestinal: Diarrhea, nausea, vomiting, abdominal
pain

Abbreviations: KD, Kawasaki disease; LV, left ventricle; MIS-C, multisystem inflammatory syndrome related to COVID-19.

(72.7% of KD patients NL63+ vs 4.5% of controls NL63+;
P = .015).Subsequently, though several case-control studies
have explored the association of coronaviruses with KD, there
has been a great deal of conflicting evidence4,5,7,11-16 (Table 2).
The differences in results may be due to differences in geographical location, study population, study design, sampling
(timing and method of collection, handling, and testing of
samples), criteria for selection of cases (inclusion of exclusion
of patients with incomplete/atypical KD) and control patients,
and coronavirus species tested for.4,5,7,11-22 Furthermore, case
series by Shimizu et al,17 Baker et al21 (both USA and The
Netherlands), Chang et al18 (Taiwan) and Cho et al20 (South
Korea) have reported HCoV positivity rates ranging from 0%
to 2% in KD patients. A case report by Bohlok et al19 (Lebanon)
in 2020 also described atypical KD following HCoV-OC43
infection in 13.5-year-old male, while one by Giray et al22
(Turkey) in 2016 described HCoV-OC43/HKU1 infection in
a 17-month-old female. Interestingly, Rowley et al23 identified
a “corona” of “spikes” surrounding viral particles in bronchial
epithelium visualized using transmission electron microscopy, a
description that is reminiscent of the crown-like projection of
spike proteins that gives the coronaviruses their name.23
However, despite more than a decade of research exploring the
association of the HCoVs with KD, no conclusive evidence has
been discovered.

COVID-19’s Cytokine Storm

Cytokines is a broad term to describe a category of proteins
that play a key role in cell signaling and the immune system.
Homeostasis is maintained by the body by a balance between
pro- and anti-inflammatory cytokines. In KD, it is proposed
that abnormal activation of the immune system results in the
release of pro-inflammatory cytokines.25 Similarly, COVID-19

has been shown to cause a massive release of pro-inflammatory
cytokines (“cytokine storm”) and immune dysregulation,
increasing disease severity24,26 and possibly precipitating multiorgan failure.27 Pro-inflammatory cytokines activate more
immune cells and promote leukocyte extravasation, causing
local tissue damage and vasculitis.25 Amongst these cytokines
is believed to be TNF-α, which mediates elastin breakdown
and eventual aneurysm formation.28 IL-6 is thought to play a
major role, as is supported by its increased levels in MIS-C29
and the effectiveness of tocilizumab (IL-6R antagonist) in
treating it.30 IL-6 expression is increased by TNF- α,30 and its
effects include promoting CD8+, Th17, and self-reactive
CD4+ cells, while inhibiting Treg cells.31 NF-κB in COVID19’s cytokine storm induces the IL-6 amplifier (IL-6 Amp),
which results in a positive feedback loop of further proinflammatory cytokine release,32 and also induces TNF- α.32
Moreover, a study demonstrated increased proinflammatory
Th17 cell activity with concomitantly decreased anti-inflammatory Treg cell function in KD.33 This change in Th17 and
Treg activity is akin to what is seen in KD,33 and murine
models have shown that inhibition of Th17 cytokines via
JAK2 inhibitor Fedratinib may prevent the adverse outcomes
of Th17-associated cytokine storm in COVID-19.34 Thus,
understandably, most MIS-C cases have demonstrated recovery after treatment with immunomodulatory agents, including
anti-TNF and IL-6 inhibitors.35

Superantigenic Behavior of SARS-CoV-2

There has been long-standing speculation that the pathogenesis of KD might involve superantigens that cause immune
dysregulation, and ultimately, a cytokine storm.36 Though
SAGs are classically bacterial, known and potential viral SAGs
include in mouse mammary tumor virus (MMTV), CMV, and

30
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1

24

USA (New
Haven)

Germany
(South
East)

USA (San
Diego)

Japan
(Tokyo)

Esper et al7

Lehmann
et al11

Belay et al12

Shirato
et al13

Duration
(months)

Country

Author
(Year)

NL63
229E

NL63
229E
OC45

NL63
229E
OC43
HKU1
SARS-CoV-1

NL6324

HCoV Species

Total: 15

Total: 10

Total: 21
Incomplete
KD: 9

Total: 11

Total: 42
Control 1:
23
(NT test with
VSV
pseudotyped
viruses)
Control 2:
29
(NT Test with
HCoV-229E)

Total: 6

Total: 33

Total: 22

2.3 Y

3.6 Y

4.5 Y

24.4 M

2.2-2.4 Y

3.3 Y

5.2 Y

23.7 M

Control

Case

Case (n)

Control (n)

Mean/Median Age

Sample size

Table 2. Case control studies exploring the association of Human Coronaviruses with KD.

Serum

OP/NP
Swab

Serum

Respiratory
Secretions

Sample
used

Serology

RT-PCR

Serology

RT-PCR

Method

(Continued)

Cases:
NL63: 47% + in Acute & Recovery
Phases
229E: 33% + in Acute % 40% +
in Recovery Phase
Control 1:
NL63: 39% +
229E: 9% +
Control 2:
NL63: 51% +
229E: 10% +
Chi-Squared P < 0.05:
229E in Recovery Phase vs.
Control 1 and 2

All samples for Cases and Control
tested negative for all strains of
HCoV

Cases:
NL63: 48% IgG +, 10% IgM +,
29% IgA +
229E: 19% IgG +, 10% IgM +,
10% IgA +
OC43: 52% IgG +, 5% IgM +,
19% IgA +
HKU1: 29% IgG +, 5% IgM +, 24%
IgA +
SARS-CoV-1: 0% IgG +, 0% IgM
+, 0% IgA+
Controls:
NL63: 67% IgG +, 3% IgM +, 21%
IgA +
229E: 21% IgG +, 3% IgM +, 6%
IgA +
OC43: 30% IgG +, 3% IgM +,
12% IgA +
HKU1: 12% IgG +, 0 % IgM +, 6%
IgA
SARS-CoV-1: 0% IgG +, 0% IgM
+, 0% IgA+
Chi-Squared Test: all p > 0.05

Cases:
72.7% NL63 +
Controls:
4.5% NL63 +
MH matched OR [95% CI]: 16.0
[3.4-74.4]
P = 0.015

Findings
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73

52

8

USA
(Denver)

Taiwan
(Taipei
and
Tao-Yuan
County)

USA
(Aurora)

South
Korea
(Seoul)

Dominguez
et al15

Chang et al4

Turnier et al5

Kim et al.16

NL63
229E
OC43

NL63
229E
OC43
HKU1

Pancoronaviruses

NL6324

NL6324

HCoV Species

Total: 55

Total: 222

Total: 226

Total: 26
Incomplete
KD: 6

Total: 19

Total: 78

Total: 16415

Total: 226

Total: 52

Total: 208

P = .028

2.77 Y

2.923.52 Y

2.07 Y

46.2 M

22.6 M

3.95 Y

-

2.01 Y

40.1 M

21.6 M

Control

Case

Case (n)

Control (n)

Mean/Median Age

Sample size

NP Swab

NP Wash

OP and NP
Swab

NP wash

NP Swab

Sample
used

RT-PCR

RT-PCR

RT-PCR
SN-PCR

RT-PCR

RT-PCR

Method

Cases:
OC43/229E: 3.6%
NL63: 0%
Controls:
OC43/229E: 1.3%
NL63: 1.3%

Cases:
NL63: 1.6%
229E: 1%
OC43: 1%
HKU1: 0%
Controls:
NL63: 0.8%
229E: 0.5%
OC43: 1.4%
HKU1: 0.5%

Cases:
7.1% + Pan-HCoV
Controls:
0.9% + Pan-HCoV

Cases:
7.7% NL63 +
Controls:
7.7% NL63 +

Cases:
0% NL63 +
Controls:
2.4% NL63 +

Findings

Abbreviations: MH, Mantel-Haenszel; NP, nasopharyngeal; NT, neutralizing test; OP, oropharyngeal; RT-PCR, reverse transcription polymerase chain reaction; SN-PCR, semi-nested polymerase chain reaction; USA, United
States of America.
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Japan
(Sapporo)

Ebihara
et al14

Duration
(months)

Country

Author
(Year)

Table 2. (Continued)
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Table 3. Cytokines and superantigens in COVID-19 and Kawasaki disease.
Cytokines/
Superantigens

COVID-19

Kawasaki disease

Proinflammatory ILs

•• IL-1B, IL-RA, IL-7, IL-8, and IL-9 are
increased in both ICU and non-ICU
patients with COVID-1926
•• IL-6/ IFN-γ ratio is higher in patients
with COVID-1931
•• IL-2R and IL-6 are significantly
elevated in patients with COVID-19,
and expression increases with disease
severity39
•• IL-6 is significantly increased in
COVID-19 patients, and its levels in
ICU patients are significantly higher
than in non-ICU patients24
•• 97% of patients with MIS-C who were
tested had IL-6 ⩾ 5.0 pg/ml, with a
median of 116.3 pg/ml overall29

•• IL-1, IL-2, IL-6, and IL-8 are upregulated in acute stage KD40
•• IL-6 is significantly elevated in KD, and it decreases post-IVIG
therapy41
•• Patients with IL-6 >66.7 pg/ml are at higher risk for KD shock
syndrome (KDSS)42
•• IL-17, IL-6, and IL-23 (TH17 cytokines) are significantly
upregulated33
•• IL-1 has been found to facilitate antibody-mediated cytotoxicity in
patients with KD43

Proinflammatory
Non-IL cytokines

•• Basic FGF, G-CSF, GM-CSF, IFN-γ,
IP-10, MCP-1, MIP-1A, MIP-1B, PDGF,
TNF-α, and VEGF are increased in
both ICU and non-ICU patients with
COVID-19, and ICU patients have
higher concentrations of G-CSF, IP-10,
MCP-1, MIP-1A, and TNF-α than
non-ICU patients26
•• TNF-α is significantly increased in
COVID-19 patients, and its levels in
ICU patients are significantly higher
than in non-ICU patients24

•• TNF-α, IFN-γ, and MCP-1 are upregulated in acute stage KD40
•• IFN-γ and TNF-α are significantly elevated in KD, and they
decrease post-IVIG therapy. TNF-α is significantly decreased
post-IVIG in patients without coronary artery lesions (CALs) and in
IVIG responders, but is slightly increased in post-IVIG patients with
CALs and in non-IVIG responders.41
•• IFN- γ and TNF have been found to facilitate antibody-mediated
cytotoxicity in patients with KD44
•• Patients with IFN-γ >8.35 pg/ml are at higher risk for KD shock
syndrome (KDSS)42

Anti-inflammatory
cytokines (IL and
Non-IL)

IL-10 is increased in both ICU and
non-ICU patients with COVID-19, and ICU
patients have higher concentrations of
IL-10 than non-ICU patients24,26

•• IL-4, and IL-10 are upregulated in acute stage KD40
•• IL-10 is significantly increased in KD, and it decreases post-IVIG41
•• Patients with IL-10 >20.85 pg/ml are at a higher risk for KD shock
syndrome (KDSS)44
•• TGF-β (Treg cytokine) is low in patients with KD33

Superantigens

The Spike (S) glycoprotein of SARSCoV-2 has a high affinity TCR Vβ-binding
epitope (P681RRA684) that is similar in
sequence and structure to bacterial SAGs,
such as Staphylococcal enterotoxin B
(SEB), and there is greater stabilization
and binding of S with TCR Vβ in a
European strain (D839Y/N/E)37

•• KD-specific serum molecules are similar to molecule associated
molecular patterns (MAMPs) from Bacillus cereus, Bacillus subtilis,
Yersinia pseudotuberculosis, and Staphylococcus aureus45
•• TSST-1 producing strains of S. aureus have been isolated in
patients with KD45
•• Hemolytic Streptococci SAGs have been implicated in KD46
•• Murine models of KD have demonstrated the induction of coronary
arteritis using a SAG found within Lactobacillus cillus casei cell wall
extract (LCWE)47

Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICU, intensive care unit; IFN, interferon;
IP-10, interferon-γ-inducible protein 10; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; PDGF, platelet derived growth factor; TGF,
transforming growth factor; TNF, tumor necrosis factor; TSST-1, toxic shock syndrome toxin 1.

EBV.36 Cheng et al37 used structural-based computational
models to demonstrate the possible superantigenic activity of
SARS-CoV-2,and noted that a rare mutation due to a single
amino acid substitution from a European strain of the virus
resulted in stabilization and stronger binding of SARSCoV-2’s spike protein with TCR Vβ.37 Considering this, it
is possible that the superantigenic activity of SARS-CoV-2
could contribute to the cytokine storm that characterizes the
MIS-C.38 Table 3 summarizes the cytokine and superantigenic
associations in KD and COVID-19.

Genetics: Possible Connections Between
SARS-CoV-2 and KD

Genetics are widely considered to play a role in the susceptibility
to KD.48 Genome-wide association studies have demonstrated

several gene variants associated with KD. These include
FCGR2A (FcγRII), ITPKC (inositol 1,4,5 triphosphate kinase
C), CD40, CASP3 (Caspase 3), multiple alleles of HLA I and
II (Human Leukocyte Antigens I and II), CD209 (CD209/
DC-SIGN), and BLK (B lymphoid tyrosine kinase).48
Due to the nature of the novel coronavirus, genetic studies
regarding SARS-CoV-2 are still nascent. However, a few
potential developments have been made. HLA associations
have been demonstrated, with HLA-B*46:01 having the lowest number of predicted binding peptides for SARS-CoV-2.49
This indicates that individuals with the allele may be particularly vulnerable to COVID-19, as was the case previously with
SARS-CoV-1.49 Moreover, HLA-B*15:03 demonstrated the
greatest ability for presenting highly conserved SARS-CoV-2
peptides shared among the HCoVs, suggesting a possibility
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that it may provide cross-protective T-cell-based immunity.49
Although neither HLA-B*46:01 nor HLA-B*15:03 have been
associated with KD, HLA-B*54:01 has been found to increase
susceptibility to the disease.50 A small proportion of COVID19 patients develop features of a cytokine release syndrome
(CRS) 1-2 weeks after onset of infection. Recent evidence suggests that IL-6 may be a key mediatory in the CRS associated
severe SARS-CoV-2 infection,51 and it is hypothesized that
IL-6 polymorphisms may predispose to severe COVID-19.52
Increased IL-6 levels also play a role in the acute hyperinflammatory response in KD, showing a potential commonality
between SARS-CoV-2 infection and KD.51
Since SARS-CoV-2 bears considerable genetic similarity to
SARS-CoV-1, it is in the realm of thought that genetic associations with SARS-CoV-1 may hold true to some extent for
SARS-CoV-2 as well. Assuming the association holds true, we
can postulate genetic links between SARS-CoV-2 and KD. To
begin with, there is an association between the FcγRIIA-R/
R131 genotype and a severe course of SARS-CoV-1,53 and the
FCGR2A (FcγRII) has been found to be associated with
increased susceptibility to KD.48 Similarly, a single nucleotide
polymorphism in the CD209 promoter is associated with
severe SARS-CoV-1 infection,54 while the CD209 gene has
been shown to be associated with increased susceptibility to
KD.48 The +874 A/T polymorphism in the IFN-γ (interferon
gamma) is associated with a higher risk of developing SARSCoV-1 infection,55 and the IFN-γ gene has been identified in
a mouse model as a candidate gene for association with KD
through its regulatory cytokine-suppressing inflammatory
response.28
Currently, there is insufficient genetic research pertaining to
SARS-CoV-2 to support any associations with KD, and the
links remain highly speculative. However, based on previous
experience with SARS-CoV-1 and MERS, MBL (MannoseBinding Lectin), CD147, CCL2, IL-12, and HLA genes have
been highlighted for consideration in playing a role in susceptibility to SARS-CoV-2 and severe COVID-19.56 With the
initiation of the COVID-19 Host Genetics Initiative,57 the
interplay of genetics with SARS-CoV-2 infection and
COVID-19 will be increasingly unraveled. This will serve to
shed more light upon the genetic associations between KD and
SARS-CoV-2.

Antibody-Dependent Enhancement

Antibody-dependent enhancement (ADE), the phenomenon
whereby dysfunctional antibodies amplify viral entry and infection instead of diminishing it, has been demonstrated in the
past with viruses, such as HIV58 and the coronaviruses, including SARS-CoV-1 and MERS-CoV.59,60 The most common
mechanism of ADE is Fc receptor (FcR)-dependent, where
binding of FcR to the virus-antibody complex augments the
attachment between the cell and the virus, thus resulting in

Clinical Medicine Insights: Pediatrics 
enhanced infectivity.58 ADE may also occur via binding of
virus-antibody complexes to complement receptors or by
induction of a conformational change in the viral glycoproteins, resulting in enhanced fusion.58
SARS-CoV-1 has demonstrated ADE in several in vitro
experiments. Antibodies generated in response to a SARSCoV-1 in a hamster model enhanced FcγRII (CD32)dependent viral entry into B cells.59 Another study using
anti-Spike immune serum reinforced that ADE in SARSCoV-1 is predominantly dependent on FcγRII (CD32).61 This
study also showed that certain immune cells are only infected
by SARS-CoV-1 in the presence of anti-Spike immune
serum.61 A different study used an HL-CZ human pneumocyte cell line isolated from a leukemia patient to demonstrate
ADE.62 The HL-CZ cells expressed both ACE2 as well as
higher levels of FcγRII (CD32), and when they were treated
with diluted anti-sera collected from SARS-CoV-1 patients,
there was increased viral infectivity, as opposed to when they
were treated with a more concentrated anti-sera.62 Furthermore,
a study found that anti-Spike antibodies increased infection in
macrophages, and this depended on an intact FcγRII extracellular and intracellular signaling domain.63 FcγRII with mutated
intracellular and normal extracellular domains were unable to
trigger ADE, despite being able to bind to the ligand.63
Similarly, MERS-CoV has also shown ADE in vitro. Wan
et al.60 demonstrated a novel mechanism for ADE in MERSCoV using Mersmab 1, a monoclonal antibody that binds to
the receptor-binding domain of MERS-CoV’s Spikeectodomain (S-e). Mersmab 1 was shown to bind MERS-CoV
S-e with the Fc receptors on human HEK293T (human kidney) cells. Controlled experiments demonstrated that
Mersmab1 mediated viral entry into HEK293T cells with
exogenously expressed Fc-receptors as well as into macrophages
with endogenously expressed Fc-receptors, but blocked viral
entry into cells expressing MERS-CoV’s receptor dipeptidyl
peptidase-4 (DPP-4). The ADE varied with the dosage of
Mersmab 1, and with the expression of viral receptors and
Fc-receptors. Cells with both Fc-receptors and DPP-4 had the
highest viral entry at the intermediate dose. Moreover, the
study demonstrated that neutralizing antibodies mimic the
function of viral receptors, binding to the spike protein and
triggering a conformational change in it, which results in
sequential proteolytic cleavage, thus mediating viral entry into
cells expressing FcR.
Various studies in the past have found that there is significant cross-reactivity between antibodies generated in response
to different coronavirus strains, suggesting the possibility of
non-specific ADE. One such study found that 7/28 (25%) of
SARS-CoV-1 patients had cross-reactive neutralizing antiMERS antibodies,64 while another found appreciable crossreactivity between MERS-CoV with 3 out of 4 of the seasonal
human coronaviruses (HKU1, 229E, OC43, and NL63
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CoV).65 Moreover, serum samples from COVID-19 patients
cross-react with nucleocapsid antigens of SARS-CoV-1,66
while antibodies against the Spike protein and receptor-binding domain (RBD) cross react with plasma from SARS-CoV-1
patients.67 The cross-reactivity is mostly with the non-RBD
regions, resulting in non-neutralizing antibodies.67
As MIS-C occurs late after infection with SARS-CoV-2,
once antibodies have developed, it may be possible that ADE
may contribute to the underlying mechanism of a pro-inflammatory cytokine storm, yet this remains to be explored.35,68 This
speculation is supported by the geographical distribution of
MIS-C, as prior outbreaks in areas with different coronavirus strains may prime for ADE due to antigenic epitope
heterogeneity.68 In the in vitro model that demonstrated ADE
of SARS-CoV-1 in HL-CZ cells, the cells were found to have
increased pro-inflammatory cytokine secretion.62 A study using
SARS-CoV-1/macaque models69 demonstrated that anti-spike
IgG in infected lungs prior to viral clearance resulted in recruitment of proinflammatory macrophages and a 5–10 fold increase
in IL-6, MCP1, and IL-8.69 Lastly, since by adulthood most
individuals develop natural immunity against coronaviruses, the
resultant antibodies may be passed to the infant transplacentally
and via breastfeeding, and may cross-react with SARS-CoV-2.
With age and with weaning, as the titers of these passive antibodies fall, ADE may occur in the presence of SARS-CoV-2
infection. Studies have highlighted this dose-dependent correlation between antibodies resulting in ADE.60,62 Such a phenomenon has been observed with other viruses such as the
Dengue virus, in which infants <1 year of age can develop dengue hemorrhagic fever with a primary dengue virus infection
due to the maternal dengue-specific antibodies.70

Complement activation

Due to its ability to cause inflammation, the complement pathway may be involved in the pathogenesis of MIS-C in COVID19. A study found that the nucleocapsid (N) proteins of
SARS-CoV-1, MERS-CoV, and SARS-CoV-2 bind to
MASP-2, the serine protease in the lectin pathway of the complement cascade, causing inflammatory lung injury.71 The
study also found complement hyper-activation in COVID-19
patients, and observed a promising suppressive effect when the
patients were treated with anti-C5a monoclonal antibody.71
Moreover, in the advanced stages of COVID-19, C3 inhibition
has the potential to broadly control systemic inflammation
affecting the microvascular beds of vital organs of the body.72 A
study exploring complement-associated microvascular injury
in cases of severe COVID-19 found striking septal capillary
injury, in addition to extensive deposits of terminal complement complexes (C5b-9) in the lungs.73 As the defining feature
of KD is vasculitis and general systemic inflammation, further
investigation into the role of complement in its pathogenesis is
warranted.
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Endotheliitis

Being a multisystem inflammatory disease that affects
mainly the medium-sized arteries, KD is known to cause
endotheliitis.74 Angiotensin Converting Enzyme 2 (ACE2)
receptors are present in arterial cells of several organs such as
the lungs, heart, kidneys, and intestines.75-77 As ACE2
receptors promote SARS-CoV-2′s entry into cells and its
replication,75 SARS-CoV-2 may cause endotheliitis via
endothelial ACE2 receptors.76 Viral inclusion bodies in
capillary endothelial cells, along with cellular infiltrates and
apoptosis of endothelial cells, confirm endotheliitis in SARSCoV-2 infection.76 The endotheliitis and resultant endothelial
dysfunction may lead to tissue edema, a procoagulant state,
and potentially, multi-organ dysfunction.77 Thus, SARSCoV-2 infection and inflammation in COVID-19 may function as “priming triggers” that accelerate KD development,
and highlight an important possible connection between
COVID-19 and KD.74 Given this, it can be hypothesized that
endotheliitis may contribute to the pathophysiological mechanism of association between KD and MIS-C.

Reactive oxygen species

Given the multisystemic inflammatory nature of KD, it has
been suggested that enhanced oxidative stress may contribute to the pathogenesis of the disease.78 The overproduction
of ROS upregulates cytokine/chemokine gene expression,
raising serum levels of TNF-α, IL-1, and IL-6.79 In addition, increased ROS may lead to activation of kinase pathways and redox-sensitive transcription factors, such as
NF-κB, which further upregulate cytokines.79 These amplify
the inflammatory process and cause tissue migration of
neutrophils and macrophages.79 In KD, the increased oxidative stress and resultant cytokine release may promote
the vasculitic changes and characteristic coronary artery
abnormalities.79
Increased ROS production may play a role in the development of MIS-C. Viral infections of the respiratory system are
often associated with pathophysiological processes culminating in oxidative stress through dysregulation of antioxidant
mechanisms.80 In SARS-CoV-2 infection, inflammatory
changes may lead to a dysregulated anti-oxidant system, causing overproduction of reactive oxygen species (ROS), which
could contribute to the pathogenesis of COVID-19 and its
progression into severe disease.80,81 In addition, inflammation
associated with SARS-CoV-2 may also cause macrophages
and neutrophils to increase their production of ROS.82 The
levels of angiotensin II (ATII) have been shown to increase
linearly in SARS-CoV-2 infection,83 and this increase
mediates an NADH/NADPH oxidase-induced production of
ROS.81 Regardless of the source, increased levels of ROS may
ultimately cause significant damage to the vascular endothelium in COVID-19.81
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Figure 1. Proposed model for pathogenesis of MIS-C in COVID-19.
Abbreviations: HLA, human leukocyte antigen; IL, interleukin; ROS, reactive oxygen species; TNF, tumor necrosis factor.

Conclusion

MIS-C represents a new entity in the spectrum of manifestations of COVID-19, with cases being reported from all over
the world. It is important to understand the pathophysiological mechanisms behind this new condition, as this will guide

progress toward diagnostics and treatments. Building on the
clinical similarities between KD and MIS-C, our review aimed
to compare pathophysiological mechanisms between the2 conditions in order to shed light on this rare manifestation of
COVID-19.

Shahbaz et al
Given the history of association of KD with coronaviruses
and other viruses,4,5,7,11-22 this review demonstrates how the
emergence of MIS-C may not be a wholly unique and unprecedented phenomenon. KD and MIS-C share a range of commonalities, including in their clinical presentation and proposed
pathophysiology. Though there is no definitive genetic link
between the two, the possibility of one cannot be excluded.
Both conditions share features of a hyper-inflammatory syndrome or cytokine storm,25,27 leading to a downstream inflammatory response, and to systemic oxidative stress, that may
cause vasculitis and precipitate multi-organ failure.77,80,81 It is
possible that antibody-dependent enhancement, a phenomenon seen in previous coronaviruses, may play a role in advancing the cytokine storm in COVID-19.59-63 Additionally, our
review also highlights the possible role of the superantigenic
behavior of SARS-CoV-2, and of the complement cascade in
contributing toward the multi-system inflammatory features of
MIS-C. Lastly, given the rarity of MIS-C, this review also
speculates, based on evidence, that geographic and genetic factors may predispose to this uncommon manifestation of
COVID-19 (Figure 1). The potential immunological and
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molecular mechanisms for the pathophysiology of MIS-C, as
discussed in this review, are summarized in Figure 2. The clinical similarities between MIS-C and KD, as well as the potential underlying pathophysiology in both conditions has
important implications when it comes to treatment options,
which are contrasted in Table 4.
Early detection and treatment are essential for the management of MIS-C in COVID-19. The WHO has published a
preliminary case framework for diagnosis, and has suggested
physicians suspect this condition when presented with a patient
who displays some or all features of KD or of toxic shock
syndrome.2 Treatment options include immunomodulatory
agents, such as IV immunoglobulins (IVIG) and corticosteroids, which have shown positive results.35 As the pandemic
continues to challenge healthcare systems with unprecedented
disease manifestations, it is vital that the medical community
be prepared to meet this challenge with evidence-based management responses. By highlighting the potential pathophysiological mechanisms that contribute to the condition, our
review holds important implications for the diagnosis and
management of the MIS-C.

Figure 2. Immune responses and viral mechanisms in the pathogenesis of MIS-C.
Abbreviations: Ab, antibody; ACE2, angiotensin-converting enzyme 2; APC, antigen presenting cell; CD4+, T helper cell; CTL, cytotoxic T cell; FcR, Fc receptor; MASP-2,
mannan-binding lectin serine protease 2; MHC, major histocompatibility complex; N protein, nucleocapsid protein; SAG, Superantigen; TCR, T cell receptor.
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Table 4. Summary of established and potential management options for MIS-C and KD.

Anti-inflammatory

Biologic

MIS-C1,84

KD10,85,86

IVIG

IVIG

Steroids

Aspirin (high dose)

Aspirin

Steroids (can consider in IVIG resistance)

IL-1Ra inhibitors (Anakinra)

If IVIG resistant, can consider:

IL-6 inhibitors (tocilizumab, siltuximab)

IL-1 inhibitors
IL-6 inhibitors
Anti-TNF (infliximab)

Ancillary

Broad-spectrum antibiotics

Antiplatelet (low-dose aspirin, clopidogrel)

Thromboprophylaxis (LMWH)

Thromboprophylaxis (LMWH, warfarin) if needed

Abbreviations: IVIG, intravenous immunoglobulins; IL, interleukin; KD, Kawasaki disease; LMWH, low molecular weight heparin; MIS-C, multisystem inflammatory
syndrome related to COVID-19; TNF, tumor necrosis factor.
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